Carl R. Illig

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia

Carl L. Manthey, Dana L. Johnson, Carl R. Illig et al. · Molecular Cancer Therapeutics · 2009 · 107 citations

Medicine, Oncology, Pharmacology +17

Synthesis of thiophene-2-carboxamidines containing 2-amino-thiazoles and their biological evaluation as urokinase inhibitors

Kenneth J. Wilson, Carl R. Illig, Nalin L. Subasinghe et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 99 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +8

Design and Optimization of Benzimidazole-Containing Transient Receptor Potential Melastatin 8 (TRPM8) Antagonists

Daniel J. Parks, William H. Parsons, Raymond W. Colburn et al. · Journal of Medicinal Chemistry · 2010 · 65 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Discovery of novel FMS kinase inhibitors as anti-inflammatory agents

Carl R. Illig, Jinsheng Chen, Mark J. Wall et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 52 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Synthesis and evaluation of novel 3,4,6-substituted 2-quinolones as FMS kinase inhibitors

Mark J. Wall, Jinsheng Chen, Sanath K. Meegalla et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 47 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14